Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2012) 120 (21): 165.

https://doi.org/10.1182/blood.V120.21.165.165

Published: 2012

Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Blood (2012) 120 (21): 3747.

https://doi.org/10.1182/blood.V120.21.3747.3747

Published: 2012

Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2010) 116 (21): 209.

https://doi.org/10.1182/blood.V116.21.209.209

Published: 2010

Journal Articles

Towards DNA-Based Monitoring of Therapy In Chronic Myeloid Leukemia

Alexander A. Morley, MD, FRACP, FRCPA, MB, BS, Paul Bartley, PhD, David Ross, MBBS, PhD, Sue Latham, BSc, Brad Budgen, B, Biotech, Susan Branford, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 2284.

https://doi.org/10.1182/blood.V116.21.2284.2284

Published: 2010

Journal Articles

Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance

Wendy T Parker, PhD, Musei Ho, Rebecca M Lawrence, Darryl L Irwin, PhD, Hamish S Scott, PhD, Timothy Hughes, MD, MBBS, Susan Branford, PhD

Blood (2010) 116 (21): 891.

https://doi.org/10.1182/blood.V116.21.891.891

Published: 2010

Journal Articles

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

Devendra K Hiwase, MD, MBBS, FRACP, FRCPA, Laura Eadie, Verity Saunders, Timothy Hughes, MD, MBBS, Deborah L. White, PhD

Blood (2010) 116 (21): 3991.

https://doi.org/10.1182/blood.V116.21.3991.3991

Published: 2010

Journal Articles

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

Carine Tang, BSc., (Hons), Lisa Schafranek, BSc., (Hons), Dale Watkins, BSc., (Hons), Wendy T Parker, PhD, Jodi Prime, BSc., Deborah L White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 3383.

https://doi.org/10.1182/blood.V116.21.3383.3383

Published: 2010

Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 356.

https://doi.org/10.1182/blood.V116.21.356.356

Published: 2010

Journal Articles

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

Devendra K Hiwase, Jane Engler, Verity Saunders, Deborah L. White, PhD, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 1205.

https://doi.org/10.1182/blood.V116.21.1205.1205

Published: 2010

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis

Ricardo Pasquini, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Luis A Meillon, MD, Lidia Mongay, MD, PhD, MBA, John Reynolds, PhD, Timothy Hughes, MD, MBBS, Dong-Wook Kim, MD

Blood (2010) 116 (21): 2292.

https://doi.org/10.1182/blood.V116.21.2292.2292

Published: 2010

Journal Articles

Imatinib PK: Observations From the TIDEL II Study

Deborah L. White, PhD, Verity Saunders, Menelaou Andrew, Allan Rofe, PhD, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 2288.

https://doi.org/10.1182/blood.V116.21.2288.2288

Published: 2010

Journal Articles

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Deborah L White, PhD, Verity A Saunders, Amity Frede, Phuong Dang, Stephanie Zrim, Michael Philip Osborn, MB, BS, Paul Manley, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 507.

https://doi.org/10.1182/blood.V114.22.507.507

Published: 2009

Journal Articles

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

Devendra K Hiwase, MD, Deborah L White, PhD, Jason A Powell, PhD, Verity A Saunders, Stephanie Zrim, Amity Frede, Mark Guthridge, Richard D'Andrea, PhD, L. Bik To, MD, Junia V. Melo, MD, PhD, Sharad Kumar, PhD, Timothy Hughes, MD

Blood (2009) 114 (22): 3250.

https://doi.org/10.1182/blood.V114.22.3250.3250

Published: 2009

Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD

Blood (2008) 112 (11): 3187.

https://doi.org/10.1182/blood.V112.11.3187.3187

Published: 2008

Journal Articles

DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML).

Alexander Morley, MD, Paul Bartley, PhD, Henry Martin-Harris, BSc, Sue Latham, BSc, David Ross, MBBS, Timothy Hughes, MD

Blood (2007) 110 (11): 2946.

https://doi.org/10.1182/blood.V110.11.2946.2946

Published: 2007

Journal Articles

Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).

Richard M. Stone, MD, Hagop M. Kantarjian, MD, Michele Baccarani, MD, Jeffrey H. Lipton, MD, Timothy Hughes, MD, Rana Ezzeddine, PhD, Eric Bleickardt, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 734.

https://doi.org/10.1182/blood.V110.11.734.734

Published: 2007

Journal Articles

A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.

Andreas Hochhaus, MD, Oliver G. Ottmann, MD, STephanie Lauber, MD, Timothy Hughes, MD, Gregor Verhoef, MD, Anthony P. Schwarer, MD, Alois Gratwohl, MD, Teresa Rafferty, RN, Debra Resta, RN, Norbert Gattermann, MD

Blood (2006) 108 (11): 2703.

https://doi.org/10.1182/blood.V108.11.2703.2703

Published: 2006

Journal Articles

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Andreas Hochhaus, MD, Philipp Erben, MD, Susan Branford, PhD, Jerald Radich, MD, D.W. Kim, MD, Giovanni Martinelli, MD, Giuseppe Saglio, MD, Martin C. Mueller, MD, Jana Hoffmann, Francesca Palandri, Simona Soverini, MD, Timothy Hughes, MD, Yaping Shou, MD PhD, Aaron Weitzman, MD, Michele Baccarani, MD

Blood (2006) 108 (11): 749.

https://doi.org/10.1182/blood.V108.11.749.749

Published: 2006

Journal Articles

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

John M. Goldman, MD, Timothy Hughes, MD, Jerry Radich, MD, Susan Branford, PhD, Andreas Hochhaus, MD, Charlene So, PharmD, Insa Gathmann, MS, Elisabeth Wehrle, Jaspal Kaeda, PhD

Blood (2005) 106 (11): 163.

https://doi.org/10.1182/blood.V106.11.163.163

Published: 2005

NARROW

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

Towards DNA-Based Monitoring of Therapy In Chronic Myeloid Leukemia

Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance

Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition

Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression.

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34 + Progenitors Is Not Significantly Different Than That Observed In CD34 - Mature Cells.

A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis

Imatinib PK: Observations From the TIDEL II Study

The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial.

Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells.

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML).

Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013).

A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.

Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure.

Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only